Platelet aggregation inhibition blocks C-reactive protein and interleukin-6 (IL-6) elevation after the coronary angioplasty: effect of the -174 G/C IL-6 gene polymorphism

Am J Cardiol. 2004 Nov 15;94(10):1300-3. doi: 10.1016/j.amjcard.2004.07.119.

Abstract

C-reactive protein (CRP), interleukin-6 (IL-6), and the -174 GC IL-6 gene polymorphism were analyzed after coronary angioplasty in 50 patients, 25 of whom were treated with the glycoprotein IIb/IIIa platelet receptor inhibitor eptifibatide for 24 hours. It was found that glycoprotein IIb/IIIa inhibition significantly blocked postangioplasty CRP increases in all patients but blocked IL-6 increases only in patients carrying the -174 GG genotype.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Angioplasty, Balloon, Coronary*
  • C-Reactive Protein / analysis*
  • Coronary Disease / blood*
  • Coronary Disease / genetics
  • Coronary Disease / therapy
  • Eptifibatide
  • Female
  • Fibrinolytic Agents / pharmacology
  • Genotype
  • Humans
  • Inflammation Mediators / blood
  • Infusions, Intravenous
  • Interleukin-6 / blood*
  • Interleukin-6 / genetics*
  • Male
  • Middle Aged
  • Peptides / administration & dosage
  • Peptides / pharmacology*
  • Platelet Aggregation Inhibitors / administration & dosage
  • Platelet Aggregation Inhibitors / pharmacology*
  • Platelet Glycoprotein GPIIb-IIIa Complex / administration & dosage
  • Platelet Glycoprotein GPIIb-IIIa Complex / pharmacology*
  • Polymorphism, Genetic*
  • Stents

Substances

  • Fibrinolytic Agents
  • Inflammation Mediators
  • Interleukin-6
  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • C-Reactive Protein
  • Eptifibatide